STRATEGIC NEWS WATCH — July 28, 2026
|
GSK’s new chief executive laid out a three-year restructuring to funnel capital into late-stage R&D ahead of a looming patent cliff, anchoring a day that also delivered a $5.5 billion J&J talc settlement, an FDA rebuke of Replimune’s melanoma data before a July 30 vote, and an “unequivocal” Altimmune GLP-1 win in alcohol use disorder. Today’s top developments:
|
What to Watch
- GSK restructuring details — As Luke Miels’ three-year plan unfolds, watch for specifics on headcount reductions, which late-stage assets receive prioritized funding, and the research-HQ relocation timeline — the clearest signals of how deep the reorganization runs.
- Replimune advisory vote (July 30, 2026) — With the FDA calling the IGNYTE data package “not interpretable,” the CTGTAC’s single-question vote on whether RP1’s melanoma efficacy is evaluable will shape the agency’s August 2 decision and signal how tolerant regulators remain of single-arm accelerated-approval packages.
- J&J talc settlement approval — The $5.5 billion proposal still needs sign-off from 95% of plaintiffs; watch whether it clears that threshold to finally resolve litigation a bankruptcy court left unsettled when it rejected an earlier, larger $9 billion plan.
- GLP-1 expansion into addiction — Altimmune’s Phase 2 win adds to mounting evidence that GLP-1 agonism modulates reward pathways; watch for larger players to accelerate licensing or in-house programs targeting alcohol and other addiction indications.
- China-sourced ADC validation — Hansoh plans a China submission while GSK holds ex-greater-China rights under a 2023 deal worth up to $1.7 billion; the ris-rez multi-tumor program is now a bellwether for Big Pharma’s bets on in-licensed Chinese oncology assets.
This brief highlights the edition’s top stories. Read the full July 28, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.